Partnership website: https://www.aspire2050.eu/p4planet/about-p4planet
P4Planet is a Horizon Europe co-programmed partnership with an overall budget of €2.6 billion, €1.3 billion from Horizon Europe and €1.3 billion for the private partners. The partnerships private partners are represented by A.SPIRE, with brings together more than 150 members.
P4Planet, the successor to the Horizon 2020 SPIRE Partnership, will aim to achieve three general objectives:
At least 10 leading sectors of the European Process Industry will be engaged in the implementation of the partnership. These include cement, steel, ceramics, chemicals, engineering, minerals and ores, non-ferrous metals, water, refineries, and pulp or paper.
The partnership works on emerging technologies and on the scaling up of already developed technologies at higher technology readiness levels (TRLs) to deliver expected CO2 emission reductions by 2030 and achieve their full impact by 2050. Proactive and continuous engagement with EU countries, regions, civil society, other research and innovation partnerships and initiatives, and other relevant stakeholders is crucial.
Contact
Partners: A.SPIRE - info@aspire2050.eu
About A.SPIRE
A.SPIRE represents innovative process industries, 20% of the total European manufacturing sector in employment and turnover, and more than 180 industrial and research process stakeholders from more than 20 countries spread throughout Europe. A.SPIRE brings together cement, ceramics, chemicals, engineering, minerals and ores, non-ferrous metals, pulp and paper, refining, steel and water sectors, several being world-leading sectors operating from Europe.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.